Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · Real-Time Price · USD

66.54

-1.64 (-2.41%)

At close: May 29, 2026, 4:00 PM EDT

66.65

+0.11 (0.17%)

After-hours: May 29, 2026, 7:31 PM EDT

Halozyme Therapeutics Revenue by Segment

Period Ending	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024
Royalties	867.84M	780.29M	699.31M	618.59M	570.99M	522.62M	482.00M	468.82M
Royalties Growth	51.99%	49.30%	45.09%	31.95%	27.49%	21.04%	15.61%	20.05%
Product Sales	376.44M	333.14M	325.57M	322.95M	303.49M	303.73M	303.64M	298.64M
Product Sales Growth	24.04%	9.68%	7.22%	8.14%	0.88%	7.55%	18.02%	30.02%
Revenues Under Collaborative Agreements	152.33M	129.42M	153.79M	142.77M	140.84M	121.00M	87.67M	95.53M
Revenues Under Collaborative Agreements Growth	8.16%	6.96%	75.42%	49.45%	74.88%	81.95%	-11.86%	12.67%

Operating Expense Breakdown

Period Ending	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024
Cost of Sales	228.77M	192.06M	186.24M	179.49M	159.42M	169.66M	175.06M	185.52M
Cost of Sales Growth	43.51%	13.20%	6.39%	-3.25%	-17.13%	-6.87%	0.22%	17.01%
Selling, General, and Administrative	207.09M	172.31M	167.47M	161.56M	154.34M	149.69M	143.72M	146.96M
Selling, General, and Administrative Growth	34.18%	15.11%	16.52%	9.94%	3.45%	0.25%	-3.23%	-12.03%
Research and Development	81.49M	70.03M	71.24M	74.74M	79.05M	79.94M	78.81M	77.50M
Research and Development Growth	3.09%	-12.40%	-9.60%	-3.56%	3.52%	3.03%	2.38%	6.55%
Amortization	76.66M	71.05M	71.05M	71.05M	71.05M	71.05M	73.63M	73.70M
Amortization Growth	7.90%	-0.00%	-3.50%	-3.60%	-3.69%	17.31%	9.22%	20.85%

Source: Business metrics provided by TipRanks and sourced from official company press releases and documents.